Suppr超能文献

硫酸镁与血小板糖蛋白IIb/IIIa抑制剂替罗非班和依替巴肽在犬类支架血栓形成模型中的抗血栓作用比较

Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.

作者信息

Rukshin Vladimir, Shah Prediman K, Cercek Bojan, Finkelstein Ariel, Tsang Vivian, Kaul Sanjay

机构信息

Vascular Physiology and Thrombosis Research Laboratory of the Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute, Los Angeles, Calif, USA.

出版信息

Circulation. 2002 Apr 23;105(16):1970-5. doi: 10.1161/01.cir.0000014612.88433.62.

Abstract

BACKGROUND

Antithrombotic effects of glycoprotein IIb/IIIa inhibitors and magnesium are known, but their comparative effects on stent thrombosis are not known. Our objective was to compare the antithrombotic effects of the glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide with magnesium in an ex vivo canine arteriovenous shunt model of stent thrombosis.

METHODS AND RESULTS

Control nitinol stents were expanded to 2 mm in diameter in a tubular perfusion chamber interposed in the shunt and exposed to flowing arterial blood at a shear rate of 2100 s(-1) for 20 minutes (n=398 perfusion runs in 24 experiments in 8 dogs). The animals were treated intravenously with MgSO4 (2 g bolus x 20 minutes followed by 2 g/h infusion), eptifibatide (double bolus of 180 microg/kg 10 minutes apart followed by 2 microg/kg per minute), or tirofiban (0.3 microg/kg per minute), with or without heparin (50 U/kg). Effects of the test agents on thrombus weight, platelet aggregation (PA), platelet CD62 expression, bleeding time (BT), heart rate, and mean arterial blood pressure were assessed. Treatment with Mg+heparin reduced stent thrombus weight by 78+/-10% compared with baseline (19+/-4 mg, P<0.001). The antithrombotic effect of Mg+heparin was equivalent to that observed with tirofiban+heparin (78+/-13%) and eptifibatide+heparin (84+/-11%). Magnesium had no significant effect on PA and BT. Tirofiban and eptifibatide inhibited PA by >90% and prolonged BT up to 20 minutes. None of the test agents had effects on CD62 expression or activated clotting time. There were no significant bleeding or hemodynamic complications.

CONCLUSION

Magnesium produced a significant reduction in acute stent thrombus formation that was equivalent in magnitude to that produced by clinically relevant doses of tirofiban and eptifibatide. Its potential use in percutaneous coronary intervention requires further study.

摘要

背景

糖蛋白IIb/IIIa抑制剂和镁的抗血栓作用已为人所知,但它们对支架内血栓形成的比较作用尚不清楚。我们的目的是在支架内血栓形成的体外犬动静脉分流模型中,比较糖蛋白IIb/IIIa抑制剂替罗非班和依替巴肽与镁的抗血栓作用。

方法与结果

将对照镍钛合金支架在置于分流管中的管状灌注室中扩张至直径2 mm,并以2100 s(-1)的剪切速率暴露于流动的动脉血中20分钟(8只犬的24项实验中进行了398次灌注运行)。动物静脉注射硫酸镁(2 g推注×20分钟,随后以2 g/h输注)、依替巴肽(两次推注,每次180 μg/kg,间隔10分钟,随后以2 μg/kg每分钟输注)或替罗非班(0.3 μg/kg每分钟),同时或不同时使用肝素(50 U/kg)。评估受试药物对血栓重量、血小板聚集(PA)、血小板CD62表达、出血时间(BT)、心率和平均动脉血压的影响。与基线相比,镁+肝素治疗使支架血栓重量减少了78±10%(19±4 mg,P<0.001)。镁+肝素的抗血栓作用与替罗非班+肝素(78±13%)和依替巴肽+肝素(84±11%)观察到的作用相当。镁对PA和BT无显著影响。替罗非班和依替巴肽抑制PA超过90%,并使BT延长至20分钟。受试药物均对CD62表达或活化凝血时间无影响。无明显出血或血流动力学并发症。

结论

镁可显著减少急性支架内血栓形成,其程度与临床相关剂量的替罗非班和依替巴肽相当。其在经皮冠状动脉介入治疗中的潜在用途需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验